IP Library › Granted Patent US 8,518,978

Granted Patent B2

US 8,518,978 · App. 12/666,785 · Granted Aug 27, 2013

Pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives

Inventors: Sun Gwan Hwang (Daejeon, KR); Sang Rak Choi (Daejeon, KR); Jeong Woo Cho (Daejeon, KR); Sung Jin Bae (Daejeon, KR); Tae Sung Koo (Daejeon, KR); So Young Lee (Daejeon, KR); Kyung Chul Cho (Daejeon, KR); Hyeon Cheol Gwon (Seoul, KR)

Assignee: SK Biopharmaceuticals Co., Ltd.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,518,978
App. No.: 12/666,785
Granted: Aug 27, 2013
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

Claims (123)

1. A method for reducing or delaying the onset of a clinical marker or symptom of restenosis or treating restenosis comprising:

administering to a subject in need thereof a pharmaceutical composition which comprises a therapeutically effective amount of a compound of Formula 1, or a pharmaceutically acceptable salt thereof:

wherein,

R 1 is furanyl or thienyl, wherein R 1 is optionally substituted with one or more substituents independently selected from the group consisting of acyl, amino, carboalkoxy, carboxy, carboxyamino, —O—(C═O)—NH 2 , cyano, halo, hydroxy, nitro, alkyl, cycloalkyl, aryl, alkoxy, aryloxy, sulfoxy and guanido,

m is 2 or 3,

A is a bond, —O—, —S—, —SO— or —SO 2 —, and

R 2 is imidazolyl, pyrazolyl, triazolyl, tetrazolyl or pyridinyl, wherein R 2 is optionally substituted with one or more substituents independently selected from the group consisting of acyl, amino, carboalkoxy, carboxy, carboxyamino, —O—(C═O)—NH 2 , cyano, halo, hydroxy, nitro, alkyl, cycloalkyl, aryl, alkoxy, aryloxy, sulfoxy and guanido.

2. A method for reducing or delaying the onset of a clinical marker or symptom of restenosis or treating restenosis comprising:

administering to a subject in need thereof a pharmaceutical composition which comprises a therapeutically effective amount of a compound selected from the group consisting of the following compounds or a pharmaceutical acceptable salt thereof:

5-furan-2-yl-isoxazole-3-carboxylic acid(3-imidazol-1-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-pyridin-2-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-pyridin-3-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-imidazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-pyridin-4-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[2-(2-methyl-imidazol-1-yl)-ethyl]-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[2-(5-methyl-imidazol-1-yl)-ethyl]-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[2-(4-methyl-imidazol-1-yl)-ethyl]-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-[1,2,4]triazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-pyrazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-[1,2,3]triazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-[1,2,3]triazol-2-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-tetrazol-2-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(2-tetrazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[3-(2-methyl-imidazol-1-yl)-propyl]-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-pyrazol-1-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-[1,2,3]triazol-1-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-[1,2,3]triazol-2-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-[1,2,4]triazol-1-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-tetrazol-1-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid(3-tetrazol-2-yl-propyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[3-(4-methyl-imidazol-1-yl)-propyl]-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(3-imidazol-1-yl-propyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(3-[1,2,4]-triazol-1-yl-propyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-imidazol-1-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-pyrazol-1-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-[1,2,4]triazol-1-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-[1,2,3]triazol-2-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-[1,2,3]triazol-1-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-pyridin-3-yl-ethyl)-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid(2-pyridin-4-yl-ethyl)-amide,

5-(5-bromo-thiophen-2-yl)-isoxazole-3-carboxylic acid(3-imidazol-1-yl-propyl)-amide,

5-furan-3-yl-isoxazole-3-carboxylic acid(3-imidazol-1-yl-propyl)-amide,

5-furan-3-yl-isoxazole-3-carboxylic acid(3-[1,2,4]-triazol-1-yl-propyl)-amide,

5-furan-3-yl-isoxazole-3-carboxylic acid(2-[1,2,4]-triazol-1-yl-ethyl)-amide,

5-thiophen-3-yl-isoxazole-3-carboxylic acid(3-[1,2,4]-triazol-1-yl-propyl)-amide,

5-thiophen-3-yl-isoxazole-3-carboxylic acid(3-imidazol-1-yl-propyl)-amide,

5-thiophen-3-yl-isoxazole-3-carboxylic acid(2-imidazol-1-yl-ethyl)-amide,

5-thiophen-3-yl-isoxazole-3-carboxylic acid(2-[1,2,4]-triazol-1-yl-ethyl)-amide,

5-furan-2-yl-isoxazole-3-carboxylic acid[2-(pyridin-2-yl-oxy)-ethyl]-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid[2-(pyridin-2-yl-oxy)-ethyl]-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid[2-(1-methyl-1H-tetrazol-5-yl-sulfanyl)-ethyl]-amide,

5-thiophen-2-yl-isoxazole-3-carboxylic acid[3-(4H-[1,2,4]triazol-3-yl-sulfanyl)-propyl]-amide, and

5-furan-2-yl-isoxazole-3-carboxylic acid[2-(4-methyl-4H-[1,2,4]triazol-3-sulfonyl)-ethyl]-amide.

3. The method of claim 1 , wherein the pharmaceutical composition further comprises rapamycin or paclitaxel.

4. The method of claim 1 , wherein the restenosis is selected from the group consisting of coronary restenosis after percutaneous transluminal coronary angioplasty (PTCA), restenosis after percutaneous intervention for cerebral and peripheral vascular diseases, vascular stenosis after various vascular surgeries, vascular stenosis after bypass operation and arteriovenous fistula angioplasty, stenosis after self-blood vessel and artificial blood vessel transplantation, and arteriosclerosis.

5. The method of claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

6. The method of claim 1 , wherein the pharmaceutical composition is parenterally administered in the form of a stent coating agent.

7. The method of claim 2 , wherein the pharmaceutical composition further comprises rapamycin or paclitaxel.

8. The method of claim 2 , wherein the restenosis is selected from the group consisting of coronary restenosis after percutaneous transluminal coronary angioplasty (PTCA), restenosis after percutaneous intervention for cerebral and peripheral vascular diseases, vascular stenosis after various vascular surgeries, vascular stenosis after bypass operation and arteriovenous fistula angioplasty, stenosis after self-blood vessel and artificial blood vessel transplantation, and arteriosclerosis.

9. The method of claim 2 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

10. The method of claim 2 , wherein the pharmaceutical composition is parenterally administered in the form of a stent coating agent.

11. The method of claim 1 , wherein R 1 is furanyl or thienyl.

12. The method of claim 1 , wherein R 2 is imidazolyl, triazolyl, tetrazolyl or pyridinyl.

13. The method of claim 1 , wherein the method is for treating restenosis and the compound is 5-furan-2-yl-isoxazole-3-carboxylic acid (2-pyridin-4-yl-ethyl)-amide.

14. The method of claim 2 , wherein the pharmaceutical formulation is administered in the form of an oral formulation, a parenteral formulation, an injectable formulation or a transcutaneous formulation.

15. The method of claim 2 , wherein the pharmaceutical formulation is administered topically.

16. The method of claim 2 , wherein the compound is selected from: